Jzp-815
Payments companies reported to CMS as associated with Jzp-815. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Jzp-815, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Jzp-815
These are the largest totals companies reported as associated with Jzp-815. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Michael Davies | Houston, TX | Medical Oncology | $3,600.00 |
| Mario Sznol | New Haven, CT | Medical Oncology | $3,600.00 |
| Edmund Kopetz | Houston, TX | Medical Oncology | $3,600.00 |
| Bruce Johnson | Boston, MA | Medical Oncology | $3,200.00 |
Prescribed Jzp-815?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.